5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 17.51▼ | 17.59▼ | 17.52▼ | 17.42▲ | 17.20▲ |
MA10 | 17.52▼ | 17.51▼ | 17.35▲ | 17.49▲ | 16.46▲ |
MA20 | 17.57▼ | 17.36▲ | 17.41▲ | 17.33▲ | 16.05▲ |
MA50 | 17.54▼ | 17.42▲ | 17.58▼ | 16.06▲ | 17.45▲ |
MA100 | 17.40▲ | 17.56▼ | 17.48▲ | 16.42▲ | 14.74▲ |
MA200 | 17.40▲ | 17.48▲ | 17.32▲ | 17.50▲ | 11.76▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.011▼ | 0.030▲ | 0.042▲ | -0.082▼ | 0.268▲ |
RSI | 38.830▼ | 53.649▲ | 51.854▲ | 53.693▲ | 53.832▲ |
STOCH | 20.332 | 68.901 | 79.101 | 52.547 | 79.832 |
WILL %R | -89.286▼ | -28.205 | -26.829 | -43.875 | -13.552▲ |
CCI | -77.306 | 23.244 | 68.292 | 1.414 | 77.077 |
Monday, June 16, 2025 06:04 AM
Teva Pharmaceutical (NYSE:TEVA) and Shanghai Fosun Pharmaceutical announced a collaboration on Monday to develop TEV-56278, a new therapy aimed at treating various cancers through an anti-PD1-IL2 ...
|
Monday, June 16, 2025 05:32 AM
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with g ...
|
Monday, June 09, 2025 04:58 PM
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 17.30 | 17.725 | 17.225 | 17.505 | 8,870,899 |
13/06/25 | 17.29 | 17.42 | 16.90 | 16.99 | 13,361,900 |
12/06/25 | 17.21 | 17.75 | 17.05 | 17.71 | 8,361,300 |
11/06/25 | 17.64 | 17.79 | 17.27 | 17.32 | 10,807,700 |
10/06/25 | 18.08 | 18.275 | 17.55 | 17.59 | 12,728,887 |
09/06/25 | 17.90 | 18.09 | 17.775 | 18.07 | 9,052,770 |
06/06/25 | 17.58 | 17.83 | 17.34 | 17.77 | 11,573,800 |
05/06/25 | 17.57 | 17.86 | 17.07 | 17.25 | 10,910,100 |
04/06/25 | 17.19 | 17.66 | 17.14 | 17.52 | 11,596,300 |
03/06/25 | 17.22 | 17.36 | 17.02 | 17.19 | 9,811,700 |
|
|
||||
|
|
||||
|
|